313 related articles for article (PubMed ID: 18026629)
1. Human papillomavirus and HPV vaccines: a review.
Cutts FT; Franceschi S; Goldie S; Castellsague X; de Sanjose S; Garnett G; Edmunds WJ; Claeys P; Goldenthal KL; Harper DM; Markowitz L
Bull World Health Organ; 2007 Sep; 85(9):719-26. PubMed ID: 18026629
[TBL] [Abstract][Full Text] [Related]
2. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
4. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
5. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
6. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.
Jenkins D
Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S18-25. PubMed ID: 18653221
[TBL] [Abstract][Full Text] [Related]
7. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
8. Quadrivalent human papillomavirus vaccine.
Barr E; Tamms G
Clin Infect Dis; 2007 Sep; 45(5):609-7. PubMed ID: 17682997
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of human papillomavirus vaccines and beyond.
Lehtinen M; Dillner J
Nat Rev Clin Oncol; 2013 Jul; 10(7):400-10. PubMed ID: 23736648
[TBL] [Abstract][Full Text] [Related]
10. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
11. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
[TBL] [Abstract][Full Text] [Related]
12. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus: current status and issues of vaccination.
Malik H; Khan FH; Ahsan H
Arch Virol; 2014 Feb; 159(2):199-205. PubMed ID: 24022639
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
[TBL] [Abstract][Full Text] [Related]
15. Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review.
Maver PJ; Poljak M
Vaccine; 2018 Aug; 36(36):5416-5423. PubMed ID: 28801154
[TBL] [Abstract][Full Text] [Related]
16. HPV-vaccination against cervical carcinoma: will it really work?
Gross G
Med Microbiol Immunol; 2007 Sep; 196(3):121-5. PubMed ID: 17318575
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus disease and vaccines.
Hutchinson DJ; Klein KC
Am J Health Syst Pharm; 2008 Nov; 65(22):2105-12. PubMed ID: 18997137
[TBL] [Abstract][Full Text] [Related]
18. Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines.
Mandic A
J BUON; 2012; 17(3):422-7. PubMed ID: 23033276
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
20. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge.
Wang R; Pan W; Jin L; Huang W; Li Y; Wu D; Gao C; Ma D; Liao S
Cancer Lett; 2020 Feb; 471():88-102. PubMed ID: 31812696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
